Cargando…
Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
PURPOSE: To evaluate the response of intravitreal aflibercept injection (IAI) in eyes with detachment of retinal pigment epithelium (DEP) secondary to nAMD refractory to monthly ranibizumab. PATIENTS AND METHODS: This is a retrospective, multicenter study. All patients received 3 IAI then treated as...
Autores principales: | Tran, Thi Ha Chau, Dumas, Stéphane, Coscas, Florence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615945/ https://www.ncbi.nlm.nih.gov/pubmed/29093970 http://dx.doi.org/10.1155/2017/8984313 |
Ejemplares similares
-
Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”
por: Tran, Thi Ha Chau, et al.
Publicado: (2018) -
Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022) -
New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
por: Patel, Prem, et al.
Publicado: (2021) -
A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
por: Johnston, Robert L., et al.
Publicado: (2017) -
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
por: Tyagi, Pallavi, et al.
Publicado: (2018)